Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions
ACC 26: MOMENTUM – Hypercortisolism in Resistant Hypertension
Author(s): Deepak L Bhatt Added: 2 weeks ago
American College of Cardiology Congress 2026 – Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us to discuss primary results from the MOMENTUM study (NCT06829537; Corcept Therapeutics) investigating the prevalence and clinical impact of endogenous hypercortisolism in patients with resistant hypertension.This prospective, cross-sectional observational study enrolled 1,143… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
New ESC Guidelines for the Management of Hypertension
Author(s): Rhian Touyz Added: 1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only… View more

Prevention & Chronic Conditions
Pathophysiology, Mechanism, Diagnosis and Management of PAH
Author(s): Apoorva Gangavelli , Ronaldo C Fabiano , Mariam Riad , et al Added: 2 months ago

Prevention & Chronic Conditions
Low-Dose Triple Pill vs Monotherapy for Hypertension
Added: 1 month ago Source:  Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ESC 25: The KARDIA-3 Study
Author(s): Neha Pagidipati Added: 7 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more

Prevention & Chronic Conditions
Left Atrial Myxoma
Author(s): Preet Shaikh , Mario Rodriguez Rivera , Michael A Beal , et al Added: 1 year ago

Prevention & Chronic Conditions
ACC 2025 Late-Breaking and Featured Science Collection
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the… View more

Intervention

Heart Failure
Jiguang Wang
Job title: Director
Dr Wang is Director of the Shanghai Institute of Hypertension, Director of the Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. At present, he is coordinating several multicentre randomised clinical trials and population- and patient-cohort studies in China. He has published 587 full-length articles on hypertension in the international… View more
Markus Schlaich
Job title: Renal Physician and Hypertension Specialist
Prof Markus Schlaich (Royal Perth Hospital and University of Western Australia, Perth, AU) is a Renal Physician and an ESH accredited Hypertension Specialist with a strong background in clinical research. His main scientific interests focus on pathophysiologic aspects of hypertension. Prof Schlaich has a specific interest in treatment modalities targeting the sympathetic nervous system and has… View more